[go: up one dir, main page]

WO2008131599A1 - Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés - Google Patents

Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés Download PDF

Info

Publication number
WO2008131599A1
WO2008131599A1 PCT/CN2007/001490 CN2007001490W WO2008131599A1 WO 2008131599 A1 WO2008131599 A1 WO 2008131599A1 CN 2007001490 W CN2007001490 W CN 2007001490W WO 2008131599 A1 WO2008131599 A1 WO 2008131599A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
peptide
amino acid
acid sequence
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/001490
Other languages
English (en)
Inventor
Jingwu Z. Zhang
Kowkkeung Walter Ho
Dongqing Zhang
Wei Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAXX GENETECH CO Ltd
Original Assignee
MAXX GENETECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAXX GENETECH CO Ltd filed Critical MAXX GENETECH CO Ltd
Priority to PCT/CN2007/001490 priority Critical patent/WO2008131599A1/fr
Publication of WO2008131599A1 publication Critical patent/WO2008131599A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Definitions

  • the present invention further relates to a method of treating rheumatoid arthritis in subject suffering from rheumatoid arthritis.
  • the method comprises administering to the subject an effective amount of an immunogenic T cell receptor peptide or combination of immunogenic T cell receptor peptides to elicit an immune response.
  • the peptide comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and immunogenic variants thereof.
  • the present invention also relates to a pharmaceutical composition for suppressing pathogenic T cell response in an individual suffering from rheumatoid arthritis.
  • the pharmaceutical composition includes an immunologically effective amount of the immunogenic peptide or combination of immunogenic peptides having an amino acid sequence corresponding to about 10 to about 20 contiguous amino acids of at least one of T cell receptor variable beta 14 (V ⁇ l4) or T cell receptor variable beta 16 (V ⁇ l6) of an individual suffering from rheumatoid arthritis.
  • the level of expression of the at least one nucleic acid having a sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 indicating a possible detection of rheumatoid arthritis in the suspected individual.
  • the pharmaceutical composition forms for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form should be sterile and fluid to the extent that syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the pharmaceutical or vaccine can also include or be administered in conjunction with an adjuvant to increase the immunogenicity of the vaccine.
  • the adjuvant used can be any adjuvant known for peptide- or protein-based vaccines.
  • the expression vectors can include one or more promoters upstream of the inserted nucleic acid that act to promote transcription of the nucleic acid and to thus promote expression of the encoded peptide.
  • the promoter can include, for example, ⁇ -actin promoter, S V40 early and late promoter, immunoglobulin promoter, human cytomegalovirus promoter, and retroviral LTRs.
  • Another method of detecting rheumatoid arthritis in an individual suspected of having rheumatoid arthritis includes the step of obtaining a tissue sample from the subject and measuring in the sample the expression level of at least one nucleic acid having a sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the level of expression of the at least one nucleotide having a sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 indicates a possible detection of rheumatoid arthritis in the suspected individual.
  • mice 6-8 weeks old, male, DBA/1 mice were purchased from Shanghai Institute of Material Medical, Chinese Academy of Sciences. Mice were maintained at the SPF graded animal facility.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Cette invention concerne des vaccins contenant des récepteurs de lymphocytes T ainsi que des procédés de préparation correspondants. Lînvention concerne également des méthodes permettant de traiter la polyarthrite rhumatoïde associée aux lymphocytes T au moyen de tels vaccins.
PCT/CN2007/001490 2007-04-30 2007-04-30 Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés Ceased WO2008131599A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/001490 WO2008131599A1 (fr) 2007-04-30 2007-04-30 Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/001490 WO2008131599A1 (fr) 2007-04-30 2007-04-30 Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés

Publications (1)

Publication Number Publication Date
WO2008131599A1 true WO2008131599A1 (fr) 2008-11-06

Family

ID=39925172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/001490 Ceased WO2008131599A1 (fr) 2007-04-30 2007-04-30 Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés

Country Status (1)

Country Link
WO (1) WO2008131599A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014116A1 (fr) * 1998-09-04 2000-03-16 Baylor College Of Medicine Peptides de lymphocytes t utilises comme therapie pour les maladies auto-immunes
JP2000300266A (ja) * 1999-04-20 2000-10-31 St Marianna Univ School Of Medicine ポリペプチド及びｄｎａ
US6423315B1 (en) * 1993-03-03 2002-07-23 The University Of Tennessee Research Corp. Synthetic peptide for treatment of autoimmune arthritis
CN1505640A (zh) * 2000-08-22 2004-06-16 ����ҽѧԺ T细胞受体Vβ-Dβ-Jβ序列及其检测方法
CN1594348A (zh) * 2003-07-02 2005-03-16 曼盛基因技术有限公司 T细胞受体cdr3的序列与类风湿性关节炎的诊断及治疗方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423315B1 (en) * 1993-03-03 2002-07-23 The University Of Tennessee Research Corp. Synthetic peptide for treatment of autoimmune arthritis
WO2000014116A1 (fr) * 1998-09-04 2000-03-16 Baylor College Of Medicine Peptides de lymphocytes t utilises comme therapie pour les maladies auto-immunes
JP2000300266A (ja) * 1999-04-20 2000-10-31 St Marianna Univ School Of Medicine ポリペプチド及びｄｎａ
CN1505640A (zh) * 2000-08-22 2004-06-16 ����ҽѧԺ T细胞受体Vβ-Dβ-Jβ序列及其检测方法
CN1594348A (zh) * 2003-07-02 2005-03-16 曼盛基因技术有限公司 T细胞受体cdr3的序列与类风湿性关节炎的诊断及治疗方法

Similar Documents

Publication Publication Date Title
EP1379552B2 (fr) Ligands de recepteur de type 5 et procedes d'utilisation
US8017584B2 (en) GD3-mimetic peptides
EP0304279B1 (fr) Déterminant peptidique associé à l'immunité
HU228354B1 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
JP2007528422A (ja) 自己免疫疾患に関与する自己抗原および非自己抗原の同定
JP2003524021A (ja) 悪性中皮腫の診断および治療のための組成物および方法
TW200906850A (en) TEM8 peptides and vaccines comprising the same
EP3833387A1 (fr) Compositions et procédés pour prévenir et traiter une infection virale
JP4422330B2 (ja) 新規な免疫異常性疾患予防・治療用剤
CN115916805A (zh) 具有延伸的氧化还原酶基序的免疫原性肽
EP1485466A2 (fr) Methodes permettant de traiter des maladies ou des troubles a l'aide de constructions peptidiques
WO1994010198A1 (fr) Procede de reduction de la resistance a plusieurs medicaments dans des cellules et des tissus
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
WO2008131599A1 (fr) Matériaux de vaccination contenant des récepteurs de lymphocytes t et procédés associés
AU2003238740B2 (en) Immunomodulatory constructs and their uses
AU2006228872A1 (en) Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope
US20030162263A1 (en) Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AU2021226544B2 (en) Tumor immune enhancer, and preparation method therefor and application thereof
WO2003061590A2 (fr) Constructions peptidiques destinees a traiter une maladie
JP2002517240A (ja) ＴＧＦβＲＩＩレセプターの核酸配列、コードされたペプチドおよび使用
CA2241023A1 (fr) Nouveaux polynucleotides et polypeptides dans des mycobacteries pathogenes et leur utilisation dans des diagnostics, des vaccins et des cibles de chimiotherapie
JP2002326999A (ja) Ｇｄ３模倣ペプチド
WO2001083689A2 (fr) Peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07721063

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, DATED 17-02-10

122 Ep: pct application non-entry in european phase

Ref document number: 07721063

Country of ref document: EP

Kind code of ref document: A1